Emergent BioSolutions (EBS) completed the sale of its Baltimore-Bayview drug substance manufacturing facility in Maryland to India's Syngene International for $36.5 million.
The sale covers the facility's assets and equipment, Emergent said Wednesday in a statement.
Emergent retains the option to access manufacturing services and capacity at the site to support future growth and pandemic response efforts in partnership with Syngene.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。